BRIACELL THERAPEUTICS CORP.

Analyst Reco. BriaCell Therapeutics Corp. Nasdaq

Equities

BCTX

CA1079301091

Delayed Nasdaq Other stock markets 11:02:04 2024-05-07 am EDT			5-day change	1st Jan Change
2.24 ^USD	-1.32%		+3.23%	-61.71%

Apr. 24	BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	MT
Apr. 10	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28	MT
BriaCell Brief: Has Reported 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients; Comes After Shares Jumped 18% on Wednesday	Dec. 28	MT
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28	CI
HC Wainwright Adjusts BriaCell Therapeutics' Price Target to $20 From $24.85, Keeps Buy Rating	23-10-03	MT
HC Wainwright Initiates BriaCell Therapeutics at Buy With $25 Price Target	22-02-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW